{
  "docId": "019de070-c58c-706c-98f1-9eec26811648",
  "docSlug": "2a1e5b2d3a1cb25fe50abb3e75ae9bdf",
  "documentTitle": "Alkermes | Investor Day Presentation Deck | 144 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 63,
  "pageCount": 132,
  "prevPage": 62,
  "nextPage": 64,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Data as of December 2020.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-c58c-706c-98f1-9eec26811648/63",
  "deckHref": "/decks/019de070-c58c-706c-98f1-9eec26811648",
  "deckJsonHref": "/decks/019de070-c58c-706c-98f1-9eec26811648.json",
  "deckAnchorHref": "/decks/019de070-c58c-706c-98f1-9eec26811648#slide-63",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.41,
        "x": 0.075,
        "y": 0.485
      },
      "kind": "list",
      "text": "Chills, pyrexia, nausea & hypotension are most frequently (>30%) reported treatment-related adverse events (TRAEs); anticipated effects of cytokine administration. Transient, majority Grade ≤2 in severity. Most frequent (>10%) Grade 3-4 TRAE was neutropenia. No discontinuations due to treatment-related AEs. No deaths due to treatment-related AEs.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "176f73db-6814-4fa0-bb7c-826611eabfcc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.43,
        "x": 0.5,
        "y": 0.485
      },
      "kind": "list",
      "text": "Chills, pyrexia & fatigue are most frequently (>30%) reported treatment-related AEs; anticipated effects of cytokine administration. Transient, all Grade ≤2 in severity. Most frequent (>10%) Grade 3-4 TRAE was neutrophil count decrease. Discontinuation due to treatment-related AEs included: fatigue, pneumonitis, infusion-related reaction, inanition. Two deaths in pancreatic cancer patients (reported at ESMO 2020). One death due to inanition and assessed by the investigator as related to nemvaleukin. One death due to underlying cancer and assessed as unrelated to treatment.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c32c9ab-6bd8-4870-8bff-c544acfe7d5a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.075,
        "w": 0.86,
        "x": 0.07,
        "y": 0.245
      },
      "kind": "paragraph",
      "text": "Safety profile of nemvaleukin in combination with pembrolizumab generally consistent with monotherapy profile. In combination, no emerging evidence of additive toxicities to those already established for pembrolizumab alone",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "726942da-04d9-475b-8eb8-de057ecab4ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.52,
        "w": 0.86,
        "x": 0.07,
        "y": 0.375
      },
      "kind": "table",
      "text": "Monotherapy (Part B only; n=42) vs Combination with Pembrolizumab (Part C only; n=111)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07a5278e-f350-4a39-b656-708f0a42401c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.355,
        "x": 0.056,
        "y": 0.125
      },
      "kind": "title",
      "text": "ARTISTRY-1 Safety Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee30cd52-8f38-4210-8dec-a74f7311d030",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 69,
      "from": 55,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "59dd9c04-c6d4-46f5-9a3a-eaa6b3829180",
      "evidence": "Slides 55-69 detail the development and potential of Nemvaleukin alfa.",
      "position": 1,
      "objective": "To present Nemvaleukin alfa as a potential game-changer in cancer treatment",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.8,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}